Skip to main content
Premium Trial:

Request an Annual Quote

Erasmus Opens Center for Bioinformatics; Signs Deals with Ingenuity, Ordina

NEW YORK, March 31 (GenomeWeb News) - The Erasmus Medical Center in Rotterdamlast week opened a new Center for Bioinformatics.

Concurrent with the launch of the center, Ingenuity said that the Erasmus MC had licensed its Ingenuity Pathways Analysis software in a deal that will give all researchers at the Erasmus MC access to the product.

In addition to licensing agreement, Ingenuity and the Erasmus MC said that they are collaborating on the development of new algorithms, visualizations, and practical applications in molecular and clinical diagnostics.

Erasmus MC is also involved in "product development in proteomics around applications developed at Ingenuity," Ingenuity said.

In another deal announced last week, the Erasmus MC said that it will collaborate with IT firm Ordina to develop bioinformatics-based diagnostic services.

Ordina and the Erasmus MC plan to provide services to analyze data from microarrays and other platforms.


This article originally appeared in BioInform, a GenomeWeb News publication.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.